T. Rowe Price Associates’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
|
|||||
|
2023
Q2 | $30.2M | Sell |
|
|||||
|
2023
Q1 | $27M | Buy |
|
|||||
|
2022
Q4 | $736K | Buy |
|
|||||
|
2022
Q3 | $479K | Sell |
|
|||||
|
2022
Q2 | $15.2M | Sell |
|
|||||
|
2022
Q1 | $18.4M | Sell |
|
|||||
|
2021
Q4 | $25.5M | Sell |
|
|||||
|
2021
Q3 | $106M | Sell |
|
|||||
|
2021
Q2 | $151M | Buy |
|
|||||
|
2021
Q1 | $105M | Sell |
|
|||||
|
2020
Q4 | $139M | Buy |
|
|||||
|
2020
Q3 | $89.6M | Sell |
|
|||||
|
2020
Q2 | $145M | Sell |
|
|||||
|
2020
Q1 | $137M | Sell |
|
|||||
|
2019
Q4 | $281M | Buy |
|
|||||
|
2019
Q3 | $81.4M | Buy |
|
|||||
|
2019
Q2 | $61.4M | Buy |
|
|||||
|
2019
Q1 | $35.8M | Buy |
|
|||||
|
2018
Q4 | $22.3M | Buy |
|
|||||
|
2018
Q3 | $32.5M | Buy |
|